Search results for "PARTICLE VACCINE"

showing 1 items of 1 documents

Structural Insight into CVB3-VLP Non-Adjuvanted Vaccine

2020

Coxsackievirus B (CVB) enteroviruses are common pathogens that can cause acute and chronic myocarditis, dilated cardiomyopathy, aseptic meningitis, and they are hypothesized to be a causal factor in type 1 diabetes. The licensed enterovirus vaccines and those currently in clinical development are traditional inactivated or live attenuated vaccines. Even though these vaccines work well in the prevention of enterovirus diseases, new vaccine technologies, like virus-like particles (VLPs), can offer important advantages in the manufacturing and epitope engineering. We have previously produced VLPs for CVB3 and CVB1 in insect cells. Here, we describe the production of CVB3-VLPs with enhanced pro…

and promotion of well-beingvirusesPROTECTS MICEPOLIOVIRUSCardiovascularcomplex mixturesvirus-like particle (VLP)virus-like particleVaccine RelatedvaccineIMMUNE-RESPONSECoxsackievirus B (CVB)COXSACKIEVIRUS B3lcsh:QH301-705.5PARTICLE VACCINE11832 Microbiology and virologyPreventionrokotteetvirus diseasesMICROSCOPYPrevention of disease and conditionsenteroviruksetHeart DiseaseInfectious DiseasesGood Health and Well Beinglcsh:Biology (General)3.4 VaccinesCoxsackievirus BENTEROVIRUS 71VIRUSImmunization3111 BiomedicineInfectionRECEPTOR-BINDINGB1Biotechnology
researchProduct